Annotation Detail
Information
- Associated Genes
- BRCA2
- Associated Variants
-
BRCA2 LOSS-OF-FUNCTION
BRCA2 LOSS-OF-FUNCTION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line.
- Variant Origin
- germline
- Variant Origin
- Rare Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1308
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7
- Variant URL
- https://civic.genome.wustl.edu/links/variants/132
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Mitomycin
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 16243825
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Mitomycin | Sensitivity | true |